NDAORALTABLET
Approved
Apr 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
STENDRA (avanafil) by Hetero is (no) in the corpus cavernosum during sexual stimulation. Approved for erectile dysfunction in adult males, erectile dysfunction (). First approved in 2012.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STENDRA (avanafil) is an oral phosphodiesterase-5 (PDE5) inhibitor approved in 2012 for the treatment of erectile dysfunction in adult males. It works by inhibiting PDE5 in the corpus cavernosum, allowing nitric oxide to increase cGMP levels and promote smooth muscle relaxation and blood inflow during sexual stimulation. Avanafil demonstrates greater than 100-fold selectivity for PDE5 over PDE6 and 1,000+ fold selectivity over other phosphodiesterase isoforms, minimizing off-target effects.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable but potentially challenged market position requiring defensive commercial strategies.
Mechanism of Action
(NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cGMP, producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Avanafil has no direct relaxant effect on isolated human…
Indications (2)
Worked on STENDRA at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.